2014
Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal Of Clinical Oncology 2014, 32: 2318-2327. PMID: 24934786, PMCID: PMC4105485, DOI: 10.1200/jco.2013.51.7367.Peer-Reviewed Original ResearchConceptsAdjuvant hormonal therapyHormonal therapyBreast cancerOlder womenInfluence of frailtyCovariate adjustmentRisk of discontinuationNonmetastatic breast cancerBreast cancer ageProportional hazards modelIIB diseaseEarly discontinuationMost patientsOlder patientsProspective cohortBaseline frailtyCancer ageHigher oddsDiscontinuationHazards modelMost womenPsychosocial dataNoninitiationTherapyLogistic regression
2010
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care
Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2010, 117: 180-189. PMID: 20939011, DOI: 10.1002/cncr.25542.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBlack PeopleBreast NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyEthnicityFemaleHealthcare DisparitiesHispanic or LatinoHormonesHumansInsurance CoverageInsurance, HealthMastectomyRacial GroupsRadiotherapy, AdjuvantSocial ClassSocioeconomic FactorsWhite PeopleConceptsDefinitive locoregional therapyHormone receptor testingArea-level socioeconomic statusBreast cancer careRace/ethnicityHormonal therapyLocoregional therapyReceptor testingSocioeconomic statusCancer careHispanic womenAdjuvant hormonal therapyAdjuvant systemic therapyInvasive breast cancerBreast cancer patientsMultivariate logistic regressionBreast cancer treatmentReceipt of careEligible patientsSystemic therapyBlack raceCancer patientsInsurance statusNational cohortBreast cancer
2006
Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer
Ligibel JA, Winer EP. Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer. Women's Health 2006, 2: 89-97. PMID: 19803930, DOI: 10.2217/17455057.2.1.89.Peer-Reviewed Original Research
2005
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Research 2005, 7: 255. PMID: 16457700, PMCID: PMC1410766, DOI: 10.1186/bcr1347.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsPostmenopausal womenEarly-stage breast cancerCourse of tamoxifenAdjuvant hormonal therapyStage breast cancerAdjuvant settingAdjuvant therapyHormonal therapyUpfront therapyOngoing trialsMajor trialsTherapeutic advancesBreast cancerTherapyInhibitorsTrialsWomenTamoxifenYearsCancer
2004
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. Journal Of Clinical Oncology 2004, 23: 619-629. PMID: 15545664, DOI: 10.1200/jco.2005.09.121.Peer-Reviewed Original ResearchConceptsReceptor-positive breast cancerHormone receptor-positive breast cancerClinical Oncology technology assessmentAromatase inhibitor therapyPostmenopausal womenAromatase inhibitorsBreast cancerEndocrine therapyAdjuvant therapyInhibitor therapyMultiple large randomized trialsOptimal adjuvant hormonal therapyHormone receptor-negative tumorsOptimal endocrine therapyTreatment-related amenorrheaAdjuvant endocrine therapyAdjuvant hormonal therapyLarge randomized trialsReceptor-negative tumorsSide effect profileUse of tamoxifenAromatase inhibitor treatmentAmerican SocietyAdjuvant settingInitial therapy
2003
The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. Journal Of The National Comprehensive Cancer Network 2003, 1: 215-21. PMID: 19768880, DOI: 10.6004/jnccn.2003.0020.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerAdjuvant hormonal therapyAromatase inhibitorsAdjuvant settingBreast cancerATAC trialHormonal therapyThird-generation aromatase inhibitor anastrozoleMost postmenopausal womenNew hormonal agentsAromatase inhibitor anastrozoleEarly breast cancerMetastatic breast cancerUse of tamoxifenRelapse-free survivalBreast cancer recurrenceAdjuvant therapyPostmenopausal patientsPostmenopausal womenThromboembolic eventsOverall mortalityHormonal agentsPatient populationUterine cancer
2002
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal Of Clinical Oncology 2002, 20: 3317-27. PMID: 12149306, DOI: 10.1200/jco.2002.06.020.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerAromatase inhibitorsBreast cancerASCO Health Services Research CommitteeAdjuvant breast cancer settingClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalAdjuvant hormonal therapyBreast cancer settingCancer-specific survivalBreast cancer incidenceIndividual health care providersHealth care providersAmerican SocietyOutcomes of interestNet health benefitAdjuvant tamoxifenASCO panelAdjuvant therapyHormonal therapyOverall survivalStandard therapy